Showing results (281-290 of 341) with videos related to

Sort By:
Pageof 35
Circulation|November 15, 2021
Empagliflozin, Health Status, and Quality of Life in Patients With Heart Failure and Preserved Ejection Fraction: The EMPEROR-Preserved TrialJaved Butler, Gerasimos Filippatos, Tariq Jamal Siddiqi, et al.
European Heart Journal|January 9, 2021
Empagliflozin and health-related quality of life outcomes in patients with heart failure with reduced ejection fraction: the EMPEROR-Reduced trialJaved Butler, Stefan D Anker, Gerasimos Filippatos, et al.
The New England Journal of Medicine|October 15, 2015
Polymer-free Drug-Coated Coronary Stents in Patients at High Bleeding RiskPhilip Urban, Ian T Meredith, Alexandre Abizaid, et al.
Pediatrics|July 3, 2004
Effect of chelation therapy on the neuropsychological and behavioral development of lead-exposed children after school entryKim N Dietrich, James H Ware, Mikhail Salganik, et al.
Eurointervention : Journal of Europcr in Collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology|June 9, 2021
Impact of clinical presentation on bleeding risk after percutaneous coronary intervention and implications for the ARC-HBR definitionFelice Gragnano, Alessandro Spirito, Noé Corpataux, et al.
BMC Medical Research Methodology|October 18, 2021
Statistical reanalysis of vascular event outcomes in primary and secondary vascular prevention trialsLisa J Woodhouse, Alan A Montgomery, Jonathan Mant, et al.
The Journal of Pediatrics|June 11, 2011
Decreased postnatal docosahexaenoic and arachidonic acid blood levels in premature infants are associated with neonatal morbiditiesCamilia R Martin, Deborah A Dasilva, Joanne E Cluette-Brown, et al.
Circulation. Cardiovascular Interventions|September 17, 2017
White Blood Cell Count and Major Adverse Cardiovascular Events After Percutaneous Coronary Intervention in the Contemporary Era: Insights From the PARIS Study (Patterns of Non-Adherence to Anti-Platelet Regimens in Stented Patients Registry)Binita Shah, Usman Baber, Stuart J Pocock, et al.
Circulation|November 11, 2020
Effect of Empagliflozin on Cardiovascular and Renal Outcomes in Patients With Heart Failure by Baseline Diabetes Status: Results From the EMPEROR-Reduced TrialStefan D Anker, Javed Butler, Gerasimos Filippatos, et al.
European Journal of Heart Failure|June 26, 2024
Incremental value of C-reactive protein to the MEESSI acute heart failure risk scoreDesiree Wussler, Maria Belkin, Samyut Shrestha, et al.
Pageof 35